CD86 and neoplasm: In a preclinical study, Wu and colleagues highlighted the immunomodulatory effects of PRRT in the murine xenograft model of human NETs, demonstrating that PRRT causes increased infiltration of CD86+ antigen presenting cells and natural killer cells into tumor tissue [38].